Generalized Anxiety Disorder (GAD) is characterized by persistent, excessive worry across multiple life domains for at least six months, accompanied by physical symptoms of anxiety. According to the National Institute of Mental Health, an estimated 2.7% of U.S. adults experience GAD in any given year, with 5.7% experiencing it at some point in their lives. Women are affected at roughly twice the rate of men.
Unlike acute anxiety triggered by specific events, GAD involves chronic worry that shifts content — work concerns one day, family concerns the next, health concerns the third — but never resolves. Many people with GAD describe themselves as “lifelong worriers” who didn’t realize their experience was clinically treatable.
DSM-5-TR Diagnostic Criteria
Per the DSM-5-TR, GAD requires:
- Excessive anxiety and worry occurring more days than not for at least 6 months
- Difficulty controlling the worry
- Three or more of the following six symptoms (only one required in children): restlessness/feeling on edge, easily fatigued, difficulty concentrating, irritability, muscle tension, sleep disturbance
- Clinically significant distress or impairment
- Not attributable to substances or another medical condition
- Not better explained by another mental disorder
The Distinguishing Feature
GAD’s hallmark is generalized worry — worry that’s not focused on a single domain but spreads across many. The content shifts:
- Work or school performance
- Financial matters
- Family members’ wellbeing
- Health (own or others’)
- Minor everyday matters — being on time, household tasks, social situations
The worry typically involves catastrophic thinking — worst-case scenarios spinning out from any starting concern.
Physical Manifestations
GAD produces real, measurable physical effects:
- Sustained muscle tension (often in shoulders, neck, jaw)
- Chronic fatigue from physiological activation
- Sleep disturbance — difficulty falling asleep or staying asleep
- Gastrointestinal symptoms — often misdiagnosed as IBS
- Tension headaches
- Difficulty concentrating
- Cardiovascular symptoms — palpitations, chest tightness
Many patients receive extensive medical workup for these symptoms before GAD is recognized as the underlying cause.
Common Comorbidities
GAD frequently coexists with other conditions:
- Major depression — Substantial overlap; one analysis found tetrachoric correlation of r=0.62 between GAD and major depression
- Other anxiety disorders
- Substance use (often self-medication)
- Sleep disorders
- Chronic pain conditions
Evidence-Based Treatment
First-line medications
Per APA practice guidelines and substantial evidence:
- SSRIs — escitalopram, sertraline, paroxetine (paroxetine FDA-approved specifically for GAD)
- SNRIs — venlafaxine extended-release and duloxetine, both FDA-approved for GAD
- Buspirone — FDA-approved for GAD; non-sedating, non-addictive; takes 2-4 weeks for effect
Second-line and adjunctive options
- Mirtazapine
- Pregabalin (not FDA-approved in U.S. for anxiety but evidence base in Europe)
- Hydroxyzine for short-term symptom relief
Benzodiazepines
The 2025 Joint Clinical Practice Guideline on Benzodiazepine Tapering (developed by APA, ASAM, AAFP, ACOG, AAN and others) recommends generally limiting benzodiazepine use to 2-4 weeks for most patients due to dependence and withdrawal risk. While benzodiazepines can provide rapid relief, they don’t address GAD’s underlying biology and long-term use produces tolerance, cognitive effects, and physical dependence.
Cognitive Behavioral Therapy
CBT for GAD has substantial evidence. Carpenter et al. (2018) meta-analysis demonstrated robust effects across anxiety disorders. CBT for GAD specifically targets:
- Cognitive restructuring around catastrophic thinking
- Worry exposure
- Intolerance of uncertainty
- Behavioral experiments
- Relaxation training
Combined treatment
For moderate-to-severe GAD, combination of medication plus CBT typically produces better outcomes than either alone.
Source: APA practice guidelines and clinical trials data.
“Just a worrier”
Many adults with GAD spend decades labeling themselves “lifelong worriers” without recognizing they have a treatable condition.
Targeted treatment
Dr. Farkas evaluates for GAD specifically and provides matched treatment — typically SSRI or SNRI plus coordination with CBT-trained therapist.
Substantial relief
Most patients with GAD experience substantial improvement in worry, sleep, physical symptoms, and quality of life with appropriate treatment.
Common Questions About GAD
How is GAD different from normal worry?
GAD involves worry that’s persistent (6+ months), excessive relative to circumstances, difficult to control, accompanied by specific physical symptoms (muscle tension, fatigue, sleep disruption, etc.), and producing functional impairment. Most people experience worry; GAD is worry as a clinical condition.
Do I need an SSRI if I’ve been a worrier my whole life?
Medication isn’t required, but for many patients with chronic GAD, SSRIs or SNRIs produce substantial improvement that decades of “trying to worry less” didn’t accomplish. The decision should be informed by severity and personal preference.
Will treatment make me less ambitious or driven?
No. Treatment reduces clinical-level worry and physical anxiety symptoms — not motivation, achievement, or concern about meaningful things. Most patients describe being more effective, not less, once chronic worry is reduced. See our related articles on anxiety disorders and high-functioning anxiety.
How long until I feel better?
SSRIs and SNRIs typically produce noticeable improvement in 2-4 weeks, with substantial response by 6-8 weeks at therapeutic dose. CBT typically produces meaningful improvement over 12-16 sessions. Both treatments build over time.